Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BCRX

3 Niche Healthcare Stocks Tackling Rare Diseases

The healthcare industry is set for growth due to advancements in targeted treatments and personalized care and the rapid evolution of medical technologies. Hence, investors might consider investing in niche healthcare stocks, Immunocore Holdings (IMCR), Catalyst Pharmaceuticals (CPRX), and BioCryst Pharmaceuticals (BCRX). Read more….

3 Under-the-Radar Biotech Stocks Revolutionizing Healthcare

3 Under-the-Radar Biotech Stocks Revolutionizing Healthcare

Hidden gems in the biotech sector are reshaping healthcare with breakthroughs in personalized medicine and rare disease treatments. Given the sector’s growing potential, I have highlighted three biotech stocks, Immunocore Holdings (IMCR), BioCryst Pharmaceuticals (BCRX), and Harmony Biosciences Holdings (HRMY) that you might consider adding to your portfolio. Read more….

3 Small-Cap Biotech Stocks to Buy for Major Upside

3 Small-Cap Biotech Stocks to Buy for Major Upside

The biotech industry is flourishing with increasing investments and breakthrough developments. Thus, fundamentally solid small-cap biotech stocks BioCryst Pharmaceuticals (BCRX), Harmony Biosciences (HRMY), and Entrada Therapeutics (TRDA) with potential upside could be worth buying. Read more.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 High-Potential Biotech Stocks Under $10

The biotech industry is witnessing rapid growth owing to its increasing demand and the inclusion of technological advancements. In this wake, investors could consider adding pocket-friendly biotech stocks Fulcrum Therapeutics (FULC), BioCryst Pharmaceuticals (BCRX), and Precision BioSciences (DTIL) to their portfolio. Continue to read….

BioCryst's Voluntary Pause Of Rare Blood Disorder Trial Turns Into FDA Clinical Hold

Tucked in its Q1 earnings release, a voluntary pause for BioCryst Pharmaceuticals Inc's (NASDAQ:BCRX) complement-mediated disease therapy has been upgraded to a partial FDA clinical hold. The update clarified why the company paused trials testing BCX9930 in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare disorder marked by the destruction of red blood cells…

What 4 Analyst Ratings Have To Say About BioCryst Pharmaceuticals

Within the last quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) has observed the following analyst ratings:

Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) has paused enrollment in clinical trials with BCX9930 as the Company investigates elevated serum creatinine levels seen in some patients. The Company will not enroll new patients in the REDEEM-1, REDEEM-2, or RENEW clinical trials during the investigation. Patients currently enrolled in the trials are continuing on the study…

inkl

Read news from The Economist, FT, and more,
with one subscription

BioCryst's Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack Rates

BioCryst's Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack Rates

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX)

BioCryst Hit 15-Year Highs But What's In Store Tomorrow For Earnings?

BioCryst Hit 15-Year Highs But What's In Store Tomorrow For Earnings?

By StoryTrading

Is BioCryst (BCRX) Ready to Breakout to New Highs on Recent Catalysts?

Is BioCryst (BCRX) Ready to Breakout to New Highs on Recent Catalysts?

By Ben Rabizadeh – Fundamentals well positioned with $1B peak sales forecast for Orladeyo and $300M influx of cash from royalty deals – Potential catalysts: update on Orladeyo sales with Q4 results on Feb. 23; BCX9930 trial enrollment underway and expect updates on progress

Organisations

US Federal Reserve

Catalyst Pharmaceuticals Inc

Entrada Therapeutics Inc

BioCryst Pharmaceuticals

Harmony Biosciences Holdings Inc

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

302,932 stories

121,333 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play